54 results about "Solid-phase synthesis" patented technology

The application provides a mung bean protein salty taste enhancing peptide, a screening and preparation method and application. The method comprises the following steps: step 1, carrying out step-by-step enzymolysis on mung bean protein by using alkaline protease and flavor protease, carrying out ultrafiltration grading, and screening an initial extract of the salty taste enhancing peptide by using an electronic tongue; step 2, further identifying polypeptide sequences by using LC-MS / MS; and step 3, screening polypeptides with strong interaction capability with salty taste receptors TMC4 and ENaC by combining biological activity prediction, target active fragment screening, safety and physicochemical property evaluation and molecular docking analysis. The salty taste enhancing peptide of the mung bean protein obtained by screening comprises polypeptides represented by RPFF, APDLRGY, WDDIGGL, FDGF and AEFF, and contains RP, RG, DD, DGF and FF characteristic peptide segments, respectively. The polypeptides are synthesized by using a solid phase, and the salty taste enhancing effect of the polypeptides is verified by using an electronic tongue. When 0.03% of the above synthesized polypeptides are added to a 0.4% NaCl solution, the salty taste enhancing rates are 90%, 62%, 34%, 52% and 42%, respectively. The polypeptides can significantly enhance salty taste perception of a solution under low-salt conditions, and achieve the effect of salt reduction without taste reduction.

The present application relates to a method for synthesizing leu-enkephalin by Fmoc method, which uses Fmoc-protected amino acid as monomer, and sequentially connects amino acid to resin. In the synthesis of leu-enkephalin, all the amino acids do not have any side chain protection group. The Fmoc protection group is removed by using a solution of 1.00 mol / L imidazole and 0.02 mol / L tricyclohexylphosphine in tetrahydrofuran, and finally leu-enkephalin is obtained by removing the resin with aqueous trifluoroacetic acid. The present application first uses imidazole and tricyclohexylphosphine as components of Fmoc deprotection agent, instead of traditional pyridine. The deprotection agent is not controlled by "controlled chemicals", is cheap and easy to obtain, is stable in nature, and is low in toxicity, volatility and corrosion. The deprotection agent has excellent Fmoc removal ability, does not cause phenolic ring acylation side reaction of tyrosine side chain, does not need any side chain protection, simplifies the production process of polypeptide, reduces the preparation cost of polypeptide, and provides great improvement space for the design of synthesis strategy of polypeptide containing basic sensitive side chain protection group.

This invention relates to the fields of molecular biology and biomedicine, disclosing plasma-active peptides with antithrombotic effects and their uses. The invention obtains various active peptides from plasma through screening and solid-phase synthesis, and confirms their biological activity through in vitro platelet aggregation experiments and in vivo arterial thrombosis model experiments. Results show that peptides 1957, 1960, and 1961 significantly inhibit collagen-induced platelet aggregation, exhibiting good antiplatelet activity; animal experiments show that peptides 1955, 1957, 1960, and 1961 significantly inhibit arterial thrombosis. These active peptides are derived from endogenous plasma components, belonging to natural antithrombotic substances, possessing good physiological compatibility and safety advantages, and reducing the risk of immunogenicity and adverse reactions. These peptides can exert antithrombotic effects without relying on traditional antiplatelet drugs, providing a new source of active molecules and treatment options for the prevention and treatment of thrombotic diseases.

The application relates to the field of polypeptide medicine preparation, and particularly discloses a preparation method of bumenol peptide, which adopts a solid-liquid combination mode, liquid-phase synthesis of a tripeptide fragment Fmoc-Lys(Ac-Nle-Asp)-OMe, subsequent solid-phase synthesis of a cyclic heptapeptide methyl ester, cleavage, cyclization, deprotection and hydrolysis to obtain crude bumenol peptide. The cyclization site is alpha-COOH of Trp and alpha-NH2 of Lys, the reaction yield is high, and the cyclization problem between Lys and Asp in most current patents is solved. The process operation is simple, the deprotection reagent is conducive to environmental protection requirements. The crude product is easy to purify, the finished product has high yield and purity, and is suitable for industrial large-scale production.

The application belongs to the technical field of biological materials, and specifically discloses an amino acid whitening polypeptide and a preparation method thereof. The structural general formula of the polypeptide is as follows: R-A-B-NH2, wherein R is a modified acyl group serving as an N terminal and having a carbon number ranging from 6 to 10, A is D-proline and a derivative thereof, and B is D-arginine and a derivative thereof. The amino whitening polypeptide is prepared by using an Fmoc solid-phase synthesis method. The whitening polypeptide has excellent melanin synthesis inhibition activity, and plays a role by targeting inhibition of TRP-1. At a concentration of 1 μM, the melanin synthesis inhibition rate of B16 cells reaches a statistically significant standard, which is significantly better than a conventional whitening agent that can only achieve a similar inhibition effect at a high concentration, and greatly reduces the effective use concentration of a whitening product.

A problem addressed by the present invention is to provide a method for efficiently producing a high-purity peptide compound at a high yield. It was discovered that an amino acid can be supported efficiently by a resin for solid-phase synthesis by bringing an amino acid solution including a specific solvent into contact with a resin for solid-phase synthesis swollen by a specific solvent, thereby solving the problem.

The application relates to a preparation method of high-adsorption-performance quinoa polypeptide aerogel. Firstly, WALTZ algorithm is used to predict and identify the easy-fibrillated quinoa polypeptide amino acid sequence of a quinoa protein fiber solution, the easy-fibrillated quinoa polypeptide amino acid sequence is obtained, and corresponding quinoa polypeptide is synthesized by adopting an Fmoc solid-phase synthesis method based on the quinoa polypeptide amino acid sequence; then the synthesized quinoa polypeptide is dissolved in water to form a quinoa polypeptide fiber solution; finally, the quinoa polypeptide fiber solution is mixed with a sodium alginate solution to prepare quinoa polypeptide aerogel. The WALTZ algorithm is used to predict the potential amino acid sequence of the quinoa protein which is easy to form a protein fiber, the Fmoc solid-phase synthesis method is used to synthesize quinoa decapeptide, and the high fibrillating capacity of the quinoa decapeptide is fully verified, so that efficient preparation of quinoa decapeptide amyloid fibers under neutral conditions is realized, and the quinoa decapeptide-sodium alginate composite aerogel with high adsorption performance for microplastics in water is prepared.

The application provides a composite silicon carbide etching ring and a preparation method thereof. The composite silicon carbide etching ring comprises: an etching ring base body which is obtained by processing a SiC blank to a target size, and the SiC blank is obtained by hot isostatic pressing of SiC powder synthesized by a solid phase synthesis method; and a SiC coating which is deposited on the etching ring base body by CVD. The preparation method comprises the following steps: synthesizing SiC powder by a solid phase method; hot isostatic pressing and sintering the SiC powder to obtain a SiC blank; machining and cleaning the SiC blank to obtain an etching ring base body; and depositing a SiC coating on the surface of the etching ring base body by CVD. The hot isostatic pressed and sintered silicon carbide is sintered in a uniform pressure and temperature field, has a more uniform structure, smaller anisotropy, high density, high mechanical strength, and stress far smaller than that of solid SiC block material prepared by a CVD method due to the uniformity of the structure; and the high-purity SiC powder + hot isostatic pressing + low-temperature CVD process as a whole guarantees the purity requirement (greater than 5N) of etching.

The application discloses a cyclic peptide compound with anti-inflammatory function and application thereof, and belongs to the technical field of polypeptide compounds, and particularly relates to a H-Phe-Lys(Boc)-Tyr(tBu)-Pro-Phe-CTC resin, i.e., a fully-protected peptide resin, which is prepared by using a solid-phase synthesis method; the fully-protected peptide resin is subjected to cutting treatment and cyclization treatment to obtain a cyclic peptide compound, and the structure of the cyclic peptide compound is Cyclo(Phe-Lys-Tyr-Pro-Phe-); the cyclization treatment further comprises deprotection cutting, and the cutting liquid in the deprotection cutting is formed by mixing TFA, Tis, EDT, PhOH and H2O.The application is a cyclic peptide compound with anti-inflammatory function, which has small cytotoxicity, good safety, can inhibit inflammatory factors and can inhibit the gene expression of inflammatory mediators, and application thereof.

This invention belongs to the field of biotechnology, specifically relating to a salty peptide from *Flammulina velutipes*, its preparation method, and its application. Water-soluble substances were extracted from different varieties of *Flammulina velutipes* using a high-pressure cooking method. The salty-umami peptides in *Flammulina velutipes* were then separated stepwise using ultrafiltration, gel chromatography, sensory evaluation, and electronic tongue analysis. Seventy-two peptides were identified using reversed-phase liquid chromatography-mass spectrometry. Two key peptides were selected for solid-phase synthesis through molecular docking with transmembrane channel-like protein 4. Electronic tongue and sensory evaluation results showed that the flavor thresholds of both synthesized peptides were higher than those of NaCl, exhibiting excellent saltiness-enhancing effects. Molecular dynamics simulation analysis of the flavor mechanism between the salty peptides and the TMC4 receptor revealed that the interaction between the peptides and the TMC4 receptor is mainly driven by hydrophobic interactions.

This application relates to the field of environmental functional technology and discloses a magnetic porous chitosan-functionalized biochar and its preparation method. The material is prepared by solid-phase synthesis from a pre-carbonized biochar precursor, chitosan, organic acid iron salt, and sodium bicarbonate. The method includes: ball milling the raw materials to obtain an ultrafine composite powder, placing it in a constant temperature and humidity environment for moisture-induced solid-phase aging to allow the components to assemble at the interface; subsequently, subjecting it to restricted pyrolysis and in-situ magnetization under an inert atmosphere, and finally washing and drying to obtain the target product. This invention employs a solid-phase mechanochemical process combined with moisture aging, avoiding pore blockage caused by liquid-phase impregnation and inhibiting nitrogen loss during pyrolysis through coordination. The obtained product has a well-developed mesoporous structure, high nitrogen doping content, and rapid magnetic response characteristics, exhibiting excellent adsorption capacity, kinetic rate, and cycling stability for heavy metals and antibiotics.

This invention relates to a pufferfish TRPV1 inhibitory peptide, its preparation method, and its application. The amino acid sequence of the peptide is LDIF. The preparation method includes: 1. Enzymatically hydrolyzing pufferfish skin, then inactivating the enzyme, and screening for peptides with a molecular weight not greater than 1 kDa from the hydrolysate, followed by freeze-drying to obtain the pufferfish skin enzymatic hydrolysate peptide; 2. Performing mass spectrometry analysis on the pufferfish skin enzymatic hydrolysate peptide, using mass spectrometry analysis software, and selecting multiple non-repeating peptide sequences based on the criteria of confidence level -10lgP > 20 and amino acid count < 10; 3. Molecularly docking the selected peptide sequences with the TRPV1 receptor using software to select peptide sequences with strong binding affinity to the TRPV1 receptor; 4. Solid-phase synthesis of the selected peptide sequences to obtain the peptide LDIF. This invention uses pufferfish skin as raw material to obtain a peptide with good inhibitory effect on TRPV1, which can be used to prepare skin care products for soothing sensitive skin.

The present invention relates to the fragment-based synthesis of peptides, in particular the peptide LL37. In specific the present invention relates to a method for fragmented solid phase synthesis of an LL37 peptide of SEQ ID NO: 1, or a variant thereof, comprising providing a first fragment of LL37, or a variant thereof, coupled to a first resin solid support by a cleavable linker, providing at least one further side chain protected fragment of LL37 coupled to a second resin solid support, wherein the fragment-resin linker is acid labile, cleaving the further side chain protected fragment(s) from the second solid support without deprotecting the side chains, and sequentially coupling the first and further fragments to produce a peptide of SEQ ID NO: 1, or a variant thereof.

The application discloses a caviar polypeptide composition with enhanced immune function, a preparation method, application and preparation, belongs to the technical field of bioactive polypeptides, and comprises at least one polypeptide with an amino acid sequence of RWFPGKPLFWRA, FWKPLRGALFPW or KWRFPGALPWFA and a molecular weight of 1400-1550 Da. The preparation method comprises caviar protein extraction, complex enzymolysis, ultrafiltration separation, chromatography purification and solid-phase synthesis. Animal experiments prove that the polypeptide can significantly enhance cell immunity, humoral immunity, monocyte-macrophage function and NK cell activity, the mechanism is related to TLR2 / TLR4 receptor activation and NF-κB / MAPK signal pathways, the safety is good, and the polypeptide is suitable for development into an immune-enhancing health food or medicine.

This invention discloses potassium borosilicate, potassium borosilicate nonlinear optical crystals, their preparation methods, and applications, belonging to the field of nonlinear optical crystal technology. The chemical formula of potassium borosilicate is K4B6Si3O. 17 With a molecular weight of 577.53, it was prepared using solid-state synthesis or vacuum encapsulation; the chemical formula of this crystal is K4B6Si3O. 17 It has a molecular weight of 577.53, belongs to the monoclinic crystal system, and has a space group of C 2. The unit cell parameters are a =11.8628(13)Å, b =6.6285(6)Å, c =11.0097(19)Å, β =117.183(4)°, unit cell volume is 770.10(17) Å. 3 The powder frequency doubling effect of the crystal is about 1.4 times that of KH2PO4 (KDP), and the ultraviolet absorption edge is shorter than 190 nm. The crystal has good chemical stability and can be used as an ultraviolet and deep ultraviolet nonlinear optical crystal in all-solid-state lasers.

The application discloses a new type of hapten and fatty acid double modified long-acting hypoglycemic BimBH3 mimetic peptide compound targeting PTP1B as well as a preparation method and application thereof. The structural general formula of the Bim BH3 mimetic peptide is shown as formula I: wherein the compound is derived from a core region peptide segment of a Bim-BH3 domain, a non-natural amino acid is used to replace the second amino acid by site-specific substitution to increase the stability of the peptide segment against DPP-4 enzyme, and a long-chain fatty acid (hexadecanoic acid or octadecanedioic acid) is conjugated to the N terminal to modify to ensure better PTP1B inhibitory activity, so that the BimBH3 mimetic peptide has longer duration and higher activity and plays a role in hypoglycemia by inhibiting the target PTP1B. The compounds are prepared by using 2-CTC resin by polypeptide solid-phase synthesis method, and the crude product is cut, purified and freeze-dried to obtain a pure target compound.

The application discloses a DPP-IV inhibitory activity peptide as well as a preparation method and application thereof. The active peptide is a pentapeptide as shown in a general formula X-P-A-P-Y, wherein X is leucine L or valine V, and the active peptide is specifically LPAPY or VPAPY, and further includes pharmaceutically acceptable salts, N-terminal acetylation modifiers and C-terminal amidation modifiers of the active peptide. The active peptide meets the requirements of a DPP-IV inhibitory activity retention rate of greater than or equal to 60% under in-vitro simulation of gastrointestinal digestion conditions, a DPP-IV inhibitory activity IC 50 value of less than or equal to 160 micromoles, and has high inhibitory activity and gastrointestinal digestion stability. The application uses silkworm chrysalis protein as raw material, and extracts the active peptide through sequential combined enzymolysis of momordica grosvenori proteinase and papain, or prepares the active peptide with high purity through a solid-phase synthesis method.

The application belongs to the technical field of sodium-ion battery positive electrode materials, and particularly relates to a method for preparing a sodium titanium manganese phosphate positive electrode material by a solid-phase method.The method comprises the following steps: adding a sodium source, a phosphorus source, a manganese source, a titanium source and a transition metal compound M into water and stirring until they are uniformly mixed, then adding a carbon source and a dispersing agent, mixing until they are uniformly mixed, and performing sand milling to obtain a precursor slurry; and performing spray drying on the precursor slurry, and then performing high-temperature sintering to obtain the sodium titanium manganese phosphate positive electrode material.The sodium titanium manganese phosphate positive electrode material prepared by the method has excellent crystallinity, high discharge capacity and high first coulomb efficiency, and good cycle stability; meanwhile, the solid-phase synthesis process is stable and controllable, and large-scale industrial production of the NMTP material is realized.The positive electrode material can be widely applied to low-speed electric vehicles, energy storage power stations and other scenes, and has a good application prospect.

Provided is a method for synthesizing semaglutide. The method mainly comprises: coupling a resin with a protected amino acid and a polypeptide fragment by means of a solid phase synthesis method to obtain a semaglutide peptide resin, and performing cleavage and purification on the semaglutide peptide resin to obtain the semaglutide, wherein the fragment comprises Gly29-Arg30, R1-Lys[AEEA-AEEA-γGlu(OR2)-C18-R3]-OH, Glu15-Gly16, Thr5-Phe6, and His1-Aib2-Glu3-Gly4. The method effectively avoids the occurrence of DKP side reactions, increases the resin weight gain rate to 98% or more, ameliorates the problem of difficult coupling caused by β-sheets, and effectively avoids the generation of impurities. In the crude peptide, the content of [D-His1] semaglutide does not exceed 0.4% and may even be 0%, the content of [D-Glu3] semaglutide does not exceed 0.19%, the contents of [Plus-Gly4] semaglutide, [D-Thr5] semaglutide, and [Plus-Gly16] semaglutide are all 0%, the content of [D-Phe6] semaglutide does not exceed 0.24%, the content of [D-γGlu15] semaglutide does not exceed 0.7%, and the content of [D-γGlu20-3] semaglutide does not exceed 0.29%; the synthesis yield reaches 70% or more; and the maximum single impurity content does not exceed 0.09%, and the total yield is 58% or more. The method greatly reduces costs and facilitates industrial production.

Disclosed herein are novel methods for the preparation and purification of oligonucleotides, such as those for use in therapy. In particular, the novel methods disclosed herein involve a three-reaction cycle of solid-phase synthesis and eliminate the need for chromatography purification.

The application discloses a preparation method of deuterium or tritium labeled oligonucleotide, which adopts a combination of solid-phase synthesis and liquid-phase synthesis for the first time, and successfully prepares 5' end deuterium or tritium labeled oligonucleotide. The application can not only precisely control the labeling site of deuterium or tritium, avoid non-specific labeling, but also significantly improve the specific activity of tritium labeled oligonucleotide, and provides a new technology for the synthesis of labeled oligonucleotide.

The present application relates to the technical field of bioengineering, in particular to a collagen peptoid and a preparation method and application thereof. The present application provides a method different from conventional solid-phase synthesis of collagen peptoids. The preparation method of the collagen peptoid provided only needs two-step reactions of polymerization (random polycondensation) and hydrogenation catalysis, and the reactions are carried out in a homogeneous solution, so that the preparation method is simple and suitable for large-scale industrialized preparation. Moreover, the structure of the collagen peptoid provided can be flexibly changed according to needs on the basis of different monomer proportions, and the target peptoid can be quickly prepared.

This invention relates to the field of biomedicine, disclosing a long-acting pTH polypeptide compound and its preparation and application. The polypeptide has an octadecanoic acid or eicosanoic acid and its derivatives modified by at least one amino acid residue at the 13th, 26th, and 27th amino acid residues of the pTH (1-34) parent peptide sequence, and is covalently bound to the polypeptide backbone via an AEEA-AEEA-γ-Glu linker. This invention significantly enhances the binding ability of the polypeptide to serum albumin and prolongs its half-life by utilizing fatty acid side chain modification. The long-acting pTH polypeptide compound of this invention exhibits significant osteogenic activity, promoting the proliferation of MC3T3-E1 cells and generating osteogenic markers and calcium nodules under osteogenic induction conditions, with a 2-6 fold increase in binding ability to serum albumin. This invention also provides a solid-phase synthesis method for this polypeptide compound and a pharmaceutical composition containing it, which can be used to treat osteoporosis and hypoparathyroidism, effectively solving the compliance problem of existing drugs requiring daily injections.

The present invention relates to the technical field of polypeptide drug preparation methods. Provided is a solid-phase preparation method for high-yield and high-purity tirzepatide. An amino resin is used as a starting resin; amino acids and small-fragment peptides are sequentially coupled according to the amino acid sequence of tirzepatide using a solid-phase synthesis method to synthesize a tirzepatide resin; and the tirzepatide resin is cleaved and purified to obtain a pure tirzepatide product. The small-fragment peptides include a 1-4 tetrapeptide fragment Boc-Tyr(tBu)-Aib-Glu(OtBu)-Gly-OH, a 5-6 dipeptide fragment Fmoc-Thr(tBu)-Phe-OH, a 7-8 dipeptide fragment Fmoc-Thr(tBu)-Ser(tBu)-OH, a 10-11 dipeptide fragment Fmoc-Tyr(tBu)-Ser(tBu)-OH, a 12-13 dipeptide fragment Fmoc-Ile-Aib-OH, a 17-18 dipeptide fragment Fmoc-Ile-Ala-OH, a 20-side-chain peptide Fmoc-Lys(AEEA-AEEA-γ-Glu(α-OtBu)-Eicosanedioic acid(mon-tBu))-OH, a 28-30 tripeptide fragment Fmoc-Ala-Gly-Gly-OH, a 32-34 tripeptide fragment Fmoc-Ser(tBu)-Ser(tBu)-Gly-OH, and a 36-38 tripeptide fragment Fmoc-Pro-Pro-Pro-OH. A coupling agent for coupling the amino acid and the small-fragment peptide is selected from Oxyma and DIC, TPTU and TMP, or COMU and DIEA.

A novel production method of a compound having a structure in which a saccharide skeleton is introduced into an amino acid derivative. When producing a glycoprotein as the compound, solid-phase synthesis of a peptide is unnecessary, formation of a non-natural structure is unnecessary, and a production method with a low degree of limitation of applicable saccharides is provided. 【Solution means】A compound represented by the following formula (where R 1 is an acetylamino group or a hydroxyl group; R 2 , R 3 , R 4 and R 5 are an alkyl group, an aryl group or an aralkyl group; G 1 is a hydrogen atom, a methyl group, or a group represented by the general formula -CH2-OX 3 ; X 1 , X 2 and X 3 are a hydrogen atom, a monovalent group having a structure in which the anomeric hydroxyl group in a saccharide is removed, etc.). TIFF2026084686000104.tif46170

This invention provides a pentavalent oxythiophosphine monomer, its asymmetric catalytic synthesis method, and its application. The structure of the pentavalent oxythiophosphine monomer is shown in Formula 3. The synthesis method involves an asymmetric catalytic coupling reaction between the intermediate compound shown in Formula 1a-3 and the compound shown in Formula 2 under the catalysis of a chiral cinchona bark catalyst, thereby generating the pentavalent oxythiophosphine monomer. Starting from key starting materials, this invention synthesizes two stereopure pentavalent oxythiophosphine monomers with configurations greater than 99% ee values ​​through a coupling reaction under the catalysis of chiral cinchona bark. This invention expands the synthesis method of stereopure oxythiophosphine monomers, and the obtained stereopure oxythiophosphine monomers can be used to synthesize stereopure pentavalent oxythiophosphine nucleoside monomers through coupling reactions. Furthermore, it enables the solid-phase synthesis of chiral PS and PS / PO mixed backbone oligonucleotides and the synthesis of PS cyclic dinucleotides, greatly promoting the research and development of chiral nucleoside drugs.

This invention belongs to the field of biomedical technology and relates to the application of PMRFamide short peptide in anti-inflammation. The amino acid sequence of PMRFamide is Pro-Met-Arg-Phe. This invention provides a method for preparing this peptide, including sequentially linking amino acids using a solid-phase synthesis method, obtaining a crude peptide through resin cleavage and precipitation, followed by purification by reversed-phase high-performance liquid chromatography and lyophilization to finally obtain a high-purity PMRFamide peptide product. This method is mature, has a high yield, and is easy to scale up for production. This invention reveals the significant effect of PMRFamide short peptide in inhibiting the release of key inflammatory mediators, exhibiting highly efficient and sustained potential anti-inflammatory activity. This tetrapeptide has a simple structure and good biocompatibility, providing a foundation for the development of novel and safe peptide anti-inflammatory drugs and showing good application prospects.

This invention discloses an antioxidant peptide derived from deep-sea cold seeps and its applications, belonging to the fields of bioinformatics, development of microbial resources in extreme environments, and antioxidant peptide technology. The antioxidant peptide CSAOP4 obtained by this invention originates from a high-salt, low-temperature, high-pressure, oligotrophic environment, exhibiting excellent stability and activity. Adding 0.1 mg / mL of this antioxidant peptide resulted in an ABTS free radical scavenging rate of 44.45%, significantly superior to CSAOP1, CSAOP2, and CSAOP3 (ABTS free radical scavenging rates of 7.32%, 15.14%, and 27.71%, respectively). It is suitable for cosmetic production processes and can be mass-produced through solid-phase synthesis, offering simple preparation and high cost-effectiveness. This deep-sea cold seep antioxidant peptide is suitable for application in the cosmetic field, significantly extending the shelf life of cosmetics and reducing the risk of oxidative deterioration, showing broad application prospects.

This invention discloses a halide solid electrolyte, electrodes, a cell, a single cell, and an electrical device. The structural formula of the halide solid electrolyte is Li. 3a MO 3a X 5‑3a This halide solid electrolyte possesses extremely high ionic conductivity. Its synthesis is a solid-phase synthesis that does not require high temperatures, making the particle size and ratio of raw materials extremely important. By refining the raw materials, the synthesis time can be further shortened in high-energy ball milling equipment, increasing production capacity and reducing energy consumption. In addition, another fatal weakness of this halide is its instability with lithium metal. It can undergo side reactions with the lithium anode, leading to interface deterioration. Therefore, it is more likely to be used for coating cathode materials and as a solid electrolyte on the cathode side in the future.